FDA assay predicts ability of mesenchymal stromal cells to suppress immune system activity
Scientists at the U.S. Food and Drug Administration (FDA) developed an assay that can predict the ability of human mesenchymal stromal cells (hMSCs) to suppress immune system activity.
The study represents an innovative use of morphological features of cells to rapidly predict future cell behavior.
hMSCs are cells derived from multiple tissue sources (such as bone marrow, fat, dental pulp, and umbilical cord) that have the unique ability to give rise to cells associated with bone, cartilage, and adipose tissue. There is also great interest in their ability to suppress unwanted immune system activation.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/dsRnEX4
No comments:
Post a Comment